Chemed (CHE) concentration risks

The company's concentration profile is defined primarily by its payor mix within the VITAS hospice business. In excess of 95% of VITAS' net patient service revenue consists of payments from Medicare and Medicaid — a high-share, mixed-character concentration. The dependency dimension is real: reimbursement rates, coverage criteria, and regulatory rules set by these two federal programs directly govern the economic terms under which the bulk of hospice services are billed and collected, meaning any adverse change to the Medicare hospice benefit structure or Medicaid reimbursement could have an immediate and large effect on revenues. The structural dimension is equally present: the hospice industry broadly depends on government payors because that is the nature of the regulatory and reimbursement framework governing end-of-life care in the United States, not a choice specific to this company. A secondary geographic concentration in Florida sits alongside the payor exposure — a medium share of the VITAS business is operated in that state, a structural concentration reflecting historical expansion and market penetration. Because Florida is also a large Medicare state with a disproportionately elderly population, the geographic and payor exposures partially overlap in their risk channels: a state-specific regulatory action or a demographic demand shift in Florida could affect both at once. No customer, supplier, or product concentration outside the hospice payor and geographic disclosures is separately identified. Investors should monitor the Medicare hospice reimbursement environment as the dominant variable.

For the engine’s reasoning on CHE’s current verdict — including which dimensions drove the score — see the per-dimension breakdown.

Concentration counts reflect items disclosed in each peer’s most recent 10-K; disclosed-size classification uses TrendMatrix’s internal 10-K extraction taxonomy.